Elekta AB Series B

Elekta AB is a human care company providing clinical solutions for treating cancer and brain disorders. Co. develops tools and treatment planning systems for radiation therapy including brachytherapy and radiosurgery, as well as workflow improving software systems across the field of cancer care. Co. has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which develops clinical solutions for radiation therapy, imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in cancer treatment based on internal radiation; and Elekta Software.
  • TickerEKTA B
  • ISINSE0000163628
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden

Analysts

Håkon Astrup ...
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl

Northern Lights

Casper Blom ...
  • Erik Moberg
  • Jan Erik Gjerland
  • Jonas Bru Lien
  • Laurits Kjærgaard
  • Mads Thinggaard
  • Øystein Elton Lodgaard
  • Peter Kurt Nielsen
  • Stefan Knutsson
  • Victor Forssell

Talking Points - Tomra (Hold): Earnings momentum set to increase

AP Møller Maersk (Hold) Post-results: Blindfolded guidance Improved earnings momentum ̶ Q1 likely to be solid Rating up to HOLD (Sell); TP up to NOK 340 (185)

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Elekta - US and Unity disappointments in Q3

Weak orders in Q3, the US remains troublesome Short-term outlook still cloudy Keep HOLD – TP 120 SEK (125)

Patrik Ling

Elekta (Buy, TP: SEK140.00) - Weak order intake in Q3

Elekta’s earnings were slightly softer than expected (sales c1% below consensus and EBITA c3% below). The real disappointment in the quarter was order intake, which was c15% below our expectations and fell c11% YOY in constant currencies. The order problem relates to the US market and the company stated that it has taken measures to rectify the issues. Elekta booked only one Unity order in the quarter. We reiterate our BUY but have trimmed our target price to SEK140 (SEK150).

Louise Cheung

Elekta AB (EKTA.B-SE): Review of 3Q20 Results

Casper Blom ...
  • Erik Moberg
  • Jan Erik Gjerland
  • Jonas Bru Lien
  • Laurits Kjærgaard
  • Mads Thinggaard
  • Øystein Elton Lodgaard
  • Peter Kurt Nielsen
  • Stefan Knutsson
  • Victor Forssell

Talking Points - Tomra (Hold): Earnings momentum set to increase

AP Møller Maersk (Hold) Post-results: Blindfolded guidance Improved earnings momentum ̶ Q1 likely to be solid Rating up to HOLD (Sell); TP up to NOK 340 (185)

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Elekta - US and Unity disappointments in Q3

Weak orders in Q3, the US remains troublesome Short-term outlook still cloudy Keep HOLD – TP 120 SEK (125)

Patrik Ling

Elekta (Buy, TP: SEK140.00) - Weak order intake in Q3

Elekta’s earnings were slightly softer than expected (sales c1% below consensus and EBITA c3% below). The real disappointment in the quarter was order intake, which was c15% below our expectations and fell c11% YOY in constant currencies. The order problem relates to the US market and the company stated that it has taken measures to rectify the issues. Elekta booked only one Unity order in the quarter. We reiterate our BUY but have trimmed our target price to SEK140 (SEK150).

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Elekta - Weaker orders and sales in Q3

EBITA -3% vs. consensus 1 Unity booked in Q3 vs ABGSCe 6 systems Share to trade down ~5% on weaker short-term outlook

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Elekta - Heads-up for report 20 February

Elekta will report its Q3 on Thursday 20 February at 07.30 CET. A conference call will follow at 10.00 CET, dial-in: SE: 3, UK: 69, US:

Elekta AB: 1 director sold

A director at Elekta AB sold 6,466 shares at 120.500SEK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Håkon Astrup ...
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl

Northern Lights

Christoffer Wang Bjørnsen ...
  • Jesper Ingildsen
  • Martin Arnell
  • Mats Bye
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Christoffer Wang Bjørnsen ...
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Patrik Ling

Northern Lights

Alexander Aukner ...
  • Jørgen Lian
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling

Northern Lights

Alexander Aukner ...
  • Frank Maaø
  • Jesper Ingildsen
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Patrik Ling
  • Simen Mortensen

Northern Lights

Louise Cheung

Elekta AB (EKTA.B-SE): Review of 3Q20 Results

ELEKTA AB sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of ELEKTA AB (SE), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 11, 2020, the closing price was SEK 119.10 and its potential was estimated at SEK 137.45.

Jill Lehman ...
  • Louise Cheung

Back-end Weighted Revenue Guidance Looks Challenging

Dan Hong ...
  • Jill Lehman

Elekta AB (EKTA.B-SE): Review of 2Q20 Results

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report

Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Varian Medical Systems (Varian or 'the company') is a leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy...

MarketLine Department

IsoRay, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's IsoRay, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by IsoRay, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlight...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Another test of support Heightened trade tensions have caused global equities to move from resistance to support in a matter of days. Additional consolidation - i.e., no breakdowns - on the broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) remains the most likely scenario. At the same time, new cracks are beginning to show and as a result we believe global equities are vulnerable to a breakdown. • New cracks emerging. Breakdowns in crude oil and new lows for the STOXX 600 Bank supersector are two recent developments which have dampened our overall outlook... see charts below. • Tes...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch